Sign in

You're signed outSign in or to get full access.

Roszell Mack III

Director at Sanara MedTech
Board

About Roszell Mack III

Roszell Mack III, age 58, is an independent director of Sanara MedTech Inc. (SMTI) first elected in 2022. He is CEO and Managing Member of Mack & Co., LLC (since 2010) and CEO and Managing Partner of Mack & Co. Partners, LP; previously co-founded Ascend Venture Group and spent more than a decade as an investment banker at Goldman Sachs and Salomon Smith Barney. He holds a BA in Engineering Sciences (Chemical) from Yale and an MBA from Harvard Business School . The Board identifies him as independent under Nasdaq rules and cites his venture capital and financial expertise as valuable .

Past Roles

OrganizationRoleTenureCommittees/Impact
Mack & Co., LLCChief Executive Officer & Managing MemberSince 2010Private investment and independent family office advisory; financial leadership
Mack & Co. Partners, LPChief Executive Officer & Managing PartnerCurrentRegistered investment adviser; investment oversight
Ascend Venture Group, LLCCo-founderPrior to 2010Technology-focused venture capital; early-stage investing
Goldman SachsInvestment bankerMore than a decadeOrigination, structuring and execution of M&A, capital raising, private placements
Salomon Smith BarneyInvestment bankerMore than a decadeM&A and financing transactions for institutional clients

External Roles

OrganizationRoleTenureNotes
Mack & Co., LLCCEO & Managing MemberSince 2010Private investment and advisory
Mack & Co. Partners, LPCEO & Managing PartnerCurrentDallas-based registered investment adviser

Board Governance

ItemDetail
IndependenceBoard determined Mack is independent under Nasdaq Listing Rules
Year first elected2022
Board meetings held (2024)4; Board also acted 7 times by unanimous written consent
Attendance (2024)Each director attended at least 75% of Board and committee meetings of which they were a member; all eight directors attended the 2024 annual meeting
CommitteeMembershipChair?Meetings in 2024
AuditMember No (Chair: Eric D. Tanzberger) 4
CompensationMember No (Chair: Sara N. Ortwein) 6
Nominating & Corporate GovernanceNot a member Chair: Robert A. DeSutter 6
Corporate DevelopmentMember No (Chair: Robert A. DeSutter) 4
  • Audit committee responsibilities include reviewing and approving related-party transactions, overseeing risk assessment (including cybersecurity), and pre-approving audit and permissible non-audit services .
  • Compensation committee responsibilities include executive compensation approvals, employment and severance arrangements, incentive plan oversight, and administering the Compensation Recovery Policy (clawback) .
  • Nominating & Corporate Governance responsibilities include director identification, slate recommendation, committee structure, governance guidelines, and CEO succession planning .

Fixed Compensation

ComponentAmountPaid inNotes
Board annual retainer$90,000Restricted common stockAnnual director retainer per policy adopted in 2023
Audit committee member fee$10,000Restricted common stockPer director compensation policy
Compensation committee member fee$5,000Restricted common stockPer director compensation policy
Corporate development committee member fee$5,000Restricted common stockPer director compensation policy
Meeting feesNone disclosedPolicy provides retainers, not meeting fees
Cash compensation$02024 non-employee director compensation shows no cash for Mack
2024 Non-Employee Director Compensation (Mack)Fees earned or paid in cash ($)Stock awards ($)All other compensation ($)Total ($)
Roszell Mack III$0 $112,697 $0 $112,697
2024 Director Equity Grant Details (Mack)Grant dateNumber of sharesIntended valueVesting
Restricted stockJune 12, 2024 3,604 $110,000 Vests June 12, 2025
  • Directors are reimbursed for reasonable travel expenses related to attendance at Board and committee meetings .
  • No pension, non-qualified deferred compensation, or non-equity incentive plan is sponsored for non-employee directors .

Performance Compensation

Performance Metric Tied to Director PayStatusEvidence
Revenue growthNot used for directorsDirector pay is annual retainer in restricted stock; no non-equity incentive plan for directors
EBITDA/EBIT targetsNot used for directorsSame as above
TSR percentileNot used for directorsSame as above
ESG goalsNot used for directorsSame as above
OptionsNone for directors in 2024 director compensationNon-employee director compensation shows only restricted stock awards

Other Directorships & Interlocks

CompanyRoleCommitteesStatusNotes
None disclosedNo other public company directorships disclosed in proxy biography
  • The governance environment includes significant related-party relationships with affiliates of the Executive Chairman/CEO (Catalyst, CGI Cellerate RX, Rochal) overseen by the audit committee; no related-party transactions involving Mack are disclosed .

Expertise & Qualifications

  • Education: BA (Engineering Sciences, Chemical) from Yale; MBA from Harvard Business School .
  • Financial and transaction expertise: venture capital co-founder; more than a decade as an investment banker (M&A, capital raising, private placements) .
  • Audit committee financial literacy: audit committee members can read and understand fundamental financial statements per Board determination .
  • Strategic development: member of corporate development committee shaping long-term strategies and reviewing strategic transactions .

Equity Ownership

HolderShares beneficially ownedBeneficial ownership %Unvested restricted stock includedAs of
Roszell Mack III13,101 Less than 1% 3,604 shares vest on June 12, 2025 April 11, 2025
Shares outstanding8,887,984 April 11, 2025
  • Insider trading policy prohibits hedging, short sales, options trading, margin accounts, or pledging company securities without advance approval of the CEO and CFO .
  • No director stock ownership guidelines are disclosed in the proxy; compliance status not disclosed .

Governance Assessment

  • Strengths: Mack is an independent director with deep finance/M&A experience, serving on audit, compensation, and corporate development committees; audit and compensation committees met regularly in 2024 (4 and 6 meetings respectively), indicating active oversight .
  • Alignment: Director compensation is equity-only via restricted stock retainers; Mack received 3,604 shares intended value $110,000 for 2024–2025 service, which vest after one year, aligning incentives with shareholder outcomes .
  • Engagement: Each director attended at least 75% of Board and committee meetings, and all directors attended the 2024 annual meeting, supporting board effectiveness .
  • Risk oversight: As an audit committee member, Mack participates in approving related-party transactions, cybersecurity/risk oversight, and auditor independence, which is critical given SMTI’s related-party exposures .
  • Potential red flags (environmental, not specific to Mack): Material related-party relationships and payments involving Catalyst, CGI Cellerate RX, Rochal, and a Catalyst services agreement (authorized up to $288,594 in 2024; $174,486 incurred in 2023) necessitate vigilant independent oversight; concentrated ownership (Executive Chairman/CEO beneficially owns 40.2%) may reduce minority investor influence .
  • Trading/pledging risk controls: SMTI’s insider trading policy bans hedging and pledging without approvals, which mitigates alignment risks; no pledging by Mack is disclosed .

Note: No Form 4 insider trading transactions for Roszell Mack III were identified in available filings returned by our tools; the proxy’s beneficial ownership table provides current ownership and vesting details .